For the quarter ended June 2025, Red River Bancshares (RRBI) reported revenue of $30.54 million, up 13.6% over the same period last year. EPS came in at $1.51, compared to $1.16 in the year-ago quarter. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence t ...

Key Takeaways Global health insurance company The Cigna Group (CI) is set to report second-quarter 2025 results on July 31, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's earnings is currently pegged at $7.14 per shareon revenues of $62.69 billion. The second-quarter earnings estimate remained stable over the past 60 days. The bottom-line projection indicates a year-over-year increase of 6.3%. Also, the Zacks Consensus Estimate for quarterly revenues suggests ye ...

Core Insights - AXIS Capital Holdings Limited (AXS) reported second-quarter 2025 operating income of $3.29 per share, exceeding the Zacks Consensus Estimate by 14.2% and reflecting a year-over-year increase of 12.2% [1][8] - The company's total operating revenues reached $1.6 billion, which was 3.2% below the Zacks Consensus Estimate but showed a year-over-year growth of 5.6% [2] - The underwriting income for AXIS Capital increased by 17.4% year over year to $189.2 million, with an improved combined ratio of 88.9% [5][8] Quarterly Operational Update - Total operating revenues were $1.6 billion, missing estimates by 3.2% but rising 5.6% year over year due to higher other insurance-related income and net premiums earned [2] - Net premiums written increased by 4% to $1.6 billion, driven by an 8.1% rise in the Insurance segment, while the Reinsurance segment saw a 9.1% decline [2] Investment Income - Net investment income decreased by 2% year over year to $187 million, primarily due to lower income from fixed maturities, partially offset by higher returns on alternative investments [3] Expense Analysis - Total expenses rose by 12.2% year over year to $1.3 billion, attributed to higher net losses, acquisition costs, and general administrative expenses [4] - Pre-tax catastrophe and weather-related losses amounted to $86 million, up from $47 million in the previous year, mainly due to California Wildfires [4] Segment Results - In the Insurance segment, gross premiums written improved by 6.5% year over year to $1.9 billion, with net premiums written increasing by 8.1% to $1.3 billion and underwriting income rising by 31.1% to $151.6 million [6] - The Reinsurance segment experienced a 6.8% decline in gross premiums written to $583.5 million, with underwriting income increasing by 17.5% to $37.5 million despite a deterioration in the combined ratio by 270 basis points to 92 [7][9] Financial Update - AXIS Capital ended the second quarter with cash and cash equivalents of $852 million, a 60% decrease from the end of 2024 [10] - Debts stood at $1.3 billion, reflecting a slight increase of 0.05% from the previous year [10] - Book value per share increased by 18.6% year over year to $70.34 as of June 30, 2025 [10] Capital Deployment - As of June 30, 2025, AXIS Capital had $110 million remaining under the board-authorized share repurchase program for common share repurchases [11]

Core Insights - Navient (NAVI) reported $131 million in revenue for the quarter ended June 2025, reflecting a year-over-year decline of 3.7% and an EPS of $0.21 compared to $0.48 a year ago [1] - The reported revenue fell short of the Zacks Consensus Estimate of $141.8 million, resulting in a surprise of -7.62%, while the EPS also missed the consensus estimate of $0.27 by -22.22% [1] Financial Performance Metrics - Net interest margin for the Consumer Lending segment was 2.3%, below the estimated 2.8% [4] - Net interest margin for the Federal Education Loan segment was 0.7%, slightly above the average estimate of 0.6% [4] - Total Non-Interest Income (Core) was $33 million, exceeding the estimated $25.12 million [4] - Other income reached $19 million, surpassing the average estimate of $13.44 million [4] - Servicing revenue was reported at $14 million, compared to the average estimate of $9.97 million [4] - Net Interest Income (Core) was $131 million, below the average estimate of $144.35 million [4] - Total core other income for Consumer Lending was $3 million, slightly below the estimated $3.06 million [4] - Net interest income (loss) for Federal Education Loans (Core) was $49 million, slightly above the average estimate of $48.59 million [4] - Total core other income for Federal Education Loans was $10 million, significantly above the average estimate of $4.38 million [4] - Net interest income (loss) for Other (Core) was reported at -$18 million, worse than the average estimate of -$14.87 million [4] - Net interest income (loss) for Consumer Lending (Core) was $113 million, slightly above the average estimate of $111.47 million [4] - Total core other income for Other was $20 million, exceeding the estimated $13.88 million [4] Stock Performance - Shares of Navient have returned -5.5% over the past month, contrasting with the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Trane Technologies reported revenue of $5.75 billion for the quarter ended June 2025, reflecting an 8.3% increase year-over-year, with EPS at $3.88 compared to $3.30 in the same quarter last year [1] - The revenue slightly missed the Zacks Consensus Estimate of $5.76 billion by 0.27%, while the EPS exceeded the consensus estimate of $3.76 by 3.19% [1] Financial Performance - Total bookings for the quarter were $5.63 billion, slightly below the average estimate of $5.65 billion [4] - Revenue from the Americas was $4.69 billion, compared to the average estimate of $4.72 billion, marking a year-over-year increase of 9.4% [4] - Revenue from EMEA was $707.9 million, exceeding the estimated $677.48 million, with a year-over-year change of 9.7% [4] - Revenue from Asia Pacific was $346.2 million, below the average estimate of $355.27 million, representing a year-over-year decline of 6.7% [4] Market Performance - Trane Technologies' shares have returned 8.5% over the past month, outperforming the Zacks S&P 500 composite's 3.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

View all Key Company Metrics for Entergy here>>> Shares of Entergy have returned +6.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Operating Revenue- Natural Gas: $40.78 million versus the three-analyst average estimate of $34.61 million. The reported number represents a year-over-year change of +15.3%. Operating Revenue- Electric: $3.27 billion versus ...

Core Viewpoint - United Therapeutics reported a revenue of $798.6 million for the quarter ended June 2025, reflecting an 11.7% increase year-over-year, and an EPS of $6.41, up from $5.85 in the previous year [1] Revenue Performance - U.S. revenues reached $759.8 million, exceeding the average estimate of $749.74 million by analysts, marking a 12.5% increase year-over-year [4] - Revenues from the Rest-of-World segment were $38.8 million, slightly above the average estimate of $33.98 million, but represented a 2.3% decline year-over-year [4] - Tyvaso generated $455.3 million in U.S. revenues, slightly above the average estimate of $452.61 million [4] - Unituxin in the U.S. brought in $55.4 million, surpassing the average estimate of $53.07 million [4] - Adcirca revenues were $6.5 million, exceeding the average estimate of $4.81 million, reflecting a 14% increase year-over-year [4] - Orenitram generated $123.9 million, above the average estimate of $118.65 million, with a 15.7% year-over-year increase [4] - Tyvaso reported $469.6 million, slightly below the average estimate of $473.16 million, but still a 17.9% increase year-over-year [4] - Remodulin revenues were $134.7 million, below the average estimate of $137.99 million, representing an 8.6% decline year-over-year [4] - Unituxin generated $58.4 million, exceeding the average estimate of $55.58 million, with a 13% year-over-year increase [4] - Tyvaso DPI revenues were $315.2 million, in line with the average estimate of $313.48 million [4] - Nebulized Tyvaso brought in $154.4 million, slightly below the average estimate of $154.53 million [4] - Other products generated $5.5 million, exceeding the average estimate of $4.95 million, reflecting a 12.2% year-over-year increase [4] Stock Performance - United Therapeutics shares returned +2.3% over the past month, compared to the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

CHONGQING, CHINA - JULY 29: In this photo illustration, a person holds a smartphone displaying the ... More logo of Bristol Myers Squibb Company (NYSE: BMY), a global biopharmaceutical firm focused on oncology, immunology, and cardiovascular diseases, with the company's purple hand-shaped branding visible in the background, on July 29, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images) Getty Images Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, ...

Group 1 - Amedisys reported $621.86 million in revenue for the quarter ended June 2025, a year-over-year increase of 5.2% [1] - The EPS for the same period was $1.54, compared to $1.32 a year ago, representing a surprise of +10.79% over the consensus estimate of $1.39 [1] - The reported revenue exceeded the Zacks Consensus Estimate of $609.65 million by +2% [1] Group 2 - Key metrics for Amedisys include Net Service Revenue for High Acuity Care at $10.7 million, a +9.2% change year-over-year [4] - Net Service Revenue for Hospice was reported at $215 million, reflecting a +5.4% year-over-year change [4] - Net Service Revenue for Home Health was $396.2 million, representing a +5% increase compared to the previous year [4] Group 3 - Amedisys shares have returned -1.5% over the past month, underperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3]

Core Insights - Sensata reported revenue of $943.38 million for the quarter ended June 2025, reflecting a year-over-year decline of 8.9% and an EPS of $0.87 compared to $0.93 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $933.26 million by 1.09%, while the EPS surpassed the consensus estimate of $0.84 by 3.57% [1] Revenue Breakdown - Net Revenue from Sensing Solutions was $291.16 million, exceeding the four-analyst average estimate of $276.84 million, with a year-over-year increase of 8.6% [4] - Net Revenue from Performance Sensing was $652.23 million, slightly below the four-analyst average estimate of $656.62 million, showing a year-over-year decline of 9.9% [4] Operating Income - Operating income for Sensing Solutions was reported at $88.04 million, surpassing the three-analyst average estimate of $83.93 million [4] - Operating income for Performance Sensing was $146.88 million, also exceeding the three-analyst average estimate of $144.84 million [4] Stock Performance - Sensata's shares have returned +9.4% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]